

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 14A  
(Rule 14a-101)**

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION  
Proxy Statement Pursuant to Section 14(a) of the Securities  
Exchange Act of 1934

Filed by the Registrant   
Filed by a Party other than the Registrant   
Check the appropriate box:

- Preliminary Proxy Statement  
 **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**  
 Definitive Proxy Statement  
 Definitive Additional Materials  
 Soliciting Material Pursuant to § 240.14a-12

---

**Ensysce Biosciences, Inc.**

(Name of Registrant as Specified in its Charter)

---

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required.  
 Fee paid previously with preliminary materials.  
 Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

---

---

**Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting**

*~Shareholder Meeting to be Held on Thursday, June 23<sup>rd</sup> at 9:00 AM PT~*

SAN DIEGO, CA, June 21, 2022 — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today reminds shareholders to vote on or before the upcoming annual shareholder meeting on Thursday, June 23<sup>rd</sup> at 9:00 AM PT/12:00 PM ET.

Shareholders will be able to attend the 2022 Annual meeting virtually via live webcast by visiting <https://agm.issuereirect.com/ensc>.

**About Ensysce Biosciences**

Ensysce Biosciences, based in San Diego, CA is a clinical-stage biotech company using its two novel proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is seeking to develop next-generation, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic costs. The platforms are covered by an extensive worldwide intellectual property portfolio encompassing a wide array of prescription drugs. For more information, please visit [www.ensysce.com](http://www.ensysce.com).

**Ensysce Biosciences Company Contact:**

Lynn Kirkpatrick, Ph.D.  
Chief Executive Officer  
(858) 263-4196

**Ensysce Biosciences Investor Relations Contact:**

Shannon Devine  
MZ North America  
Main: 203-741-8811  
[ENSC@mzgroup.us](mailto:ENSC@mzgroup.us)

Source: Ensysce Biosciences Inc.

---